PMID- 23691633
OWN - NLM
STAT- MEDLINE
DCOM- 20130709
LR  - 20131121
IS  - 0125-1562 (Print)
IS  - 0125-1562 (Linking)
VI  - 44
IP  - 2
DP  - 2013 Mar
TI  - Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients 
      after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand.
PG  - 232-43
AB  - A retrospective study was conducted by reviewing 459 medical records of adult 
      treatment naive HIV patients who received a fixed dose combination of GPO-VIR-S 
      (stavudine, lamivudine and nevirapine) or GPO-VIR-Z (zidovudine, lamivudine and 
      nevirapine) at Ramathibodi Hospital in Bangkok, Thailand during 2002-2009 
      following Thai National Treatment Guideline for adults with HIV. The aim of this 
      study was to assess the association between the baseline CD4 cell count and 
      outcome. The median CD4 cell count at baseline, 6, 12 and 102 months were 102 
      cells/microl, 213 cells/microl, 274 cells/microl and 423 cells/microl. The 
      virologic response (p=0.327), virologic rebound (p=0.626), adverse effects of 
      anti-retroviral therapy (ART) (p=0.976), switching to other ART (p=0.245), 
      occurrence of immune reconstitution inflammatory syndrome (IRIS) (p>0.05) and 
      occurrence of drug resistance (p=0.952) were not significantly associated with 
      baseline CD4 count. The Kaplan-Meier estimate showed the median time (95% CI) to 
      achieve virologic response was 10.4 (9.8-11.0) months and the median time to 
      achieve virologic rebound was 30.0 (21.6-38.4) months after initiation of ART. 
      Analysis showed the median time to achieved virologic response (p=0.401) and 
      virologic rebound (p=0.562) were not significantly associated with the baseline 
      CD4 count. This study shows the outcome after onset of ART did not vary by 
      baseline CD4 cell count.
FAU - Kyaw, Nyan Lin
AU  - Kyaw NL
AD  - Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol 
      University, Bangkok, Thailand.
FAU - Thanachartwet, Vipa
AU  - Thanachartwet V
FAU - Kiertiburanakul, Sasisopin
AU  - Kiertiburanakul S
FAU - Desakorn, Varunee
AU  - Desakorn V
FAU - Chamnanchanunt, Supat
AU  - Chamnanchanunt S
FAU - Chierakul, Wirongrong
AU  - Chierakul W
FAU - Manosuthi, Weerawat
AU  - Manosuthi W
FAU - Pitisuttithum, Punnee
AU  - Pitisuttithum P
FAU - Sungkanuparph, Somnuek
AU  - Sungkanuparph S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Southeast Asian J Trop Med Public Health
JT  - The Southeast Asian journal of tropical medicine and public health
JID - 0266303
RN  - 0 (Anti-HIV Agents)
RN  - 0 (stavudine, lamivudine, nevirapine drug combination)
RN  - 2T8Q726O95 (Lamivudine)
RN  - 4B9XT59T7S (Zidovudine)
RN  - 99DK7FVK1H (Nevirapine)
RN  - BO9LE4QFZF (Stavudine)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/administration & dosage/adverse effects/*therapeutic use
MH  - CD4 Lymphocyte Count
MH  - Female
MH  - HIV Infections/*blood/*drug therapy/epidemiology
MH  - Hematologic Tests
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/epidemiology
MH  - Kaplan-Meier Estimate
MH  - Lamivudine/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Nevirapine/administration & dosage/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Stavudine/administration & dosage/adverse effects/*therapeutic use
MH  - Thailand/epidemiology
MH  - Treatment Outcome
MH  - Viral Load
MH  - Zidovudine/administration & dosage/adverse effects/*therapeutic use
EDAT- 2013/05/23 06:00
MHDA- 2013/07/10 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/05/23 06:00 [entrez]
PHST- 2013/05/23 06:00 [pubmed]
PHST- 2013/07/10 06:00 [medline]
PST - ppublish
SO  - Southeast Asian J Trop Med Public Health. 2013 Mar;44(2):232-43.